200240 Annual Exploration of Injury Data Issues

Monday, November 9, 2009

Donna Pickett, RHIA, MPH , National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD
N. Clay Mann Mann, PhD, MS , School of Medicine, University of Utah, Salty Lake City, UT
Lois Fingerhut, MA , Injury Epidemiologist, Consultant, Washington, DC
David E. Clark, MD MPH , Center for Outcomes Research and Evaluation, Maine Medical Center, Portland, ME
Joseph L. Annest, PhD , National Center for Injury Prevention and Control/OSP, Centers for Disease Control and Prevention, Atlanta, GA
Larry Cook, PhD, MStat , Intermountain Injury Control Center, University of Utah, Salt Lake City, UT

This session will continue the tradition of the past decade of APHA meetings, where members discuss current issues in injury data. Topics for this year's Data Roundtable include:

        An update from the National Trauma Databank (NTDB), the largest aggregation of trauma registry data ever assembled, and an associated National Sample Project.

        National EMS Information System (NEMSIS) an effort to create a national EMS database.

        Two new WISQARS modules, injury mortality mapping (US, state, and county-level maps) and cost of injury.

        An update of efforts to improve E-coding in state-based hospital discharge and emergency department data systems.

        New ICD-9-CM poisoning and external cause of injury (activity, work/non-work status, operations of war) codes

        There will also be a discussion of current issues in international injury data.

Learning Objectives:
1) increase data expertise among participants 2) discuss difficult data issues and explore potential solutions 3) develop and disseminate advocacy strategies for data quality improvement

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been the chair of the ICE on Injury Statistics for 15 years/
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.